SOPHiA GENETICS (NASDAQ:SOPH) Trading Up 2.8% – Time to Buy?

SOPHiA GENETICS SA (NASDAQ:SOPH)’s stock price rose 2.8% on Friday . The stock traded as high as $4.75 and last traded at $4.73. Approximately 45,371 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 73,308 shares. The stock had previously closed at $4.60.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Wall Street Zen raised shares of SOPHiA GENETICS to a “hold” rating in a research note on Saturday, November 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Wednesday, October 8th. Finally, BTIG Research raised their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, November 10th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.00.

SOPHiA GENETICS Stock Up 2.8%

The firm has a market cap of $319.65 million, a P/E ratio of -10.28 and a beta of 1.10. The stock’s 50 day simple moving average is $4.59 and its 200 day simple moving average is $3.87. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.62 and a current ratio of 2.80.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). The business had revenue of $19.46 million during the quarter, compared to the consensus estimate of $18.13 million. SOPHiA GENETICS had a negative net margin of 41.13% and a negative return on equity of 37.75%. Research analysts anticipate that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Institutional Trading of SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SOPH. Savvy Advisors Inc. purchased a new stake in shares of SOPHiA GENETICS in the third quarter worth approximately $48,000. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS during the third quarter worth $49,000. GSA Capital Partners LLP purchased a new stake in SOPHiA GENETICS in the 3rd quarter valued at $59,000. Susquehanna International Group LLP bought a new position in SOPHiA GENETICS during the 3rd quarter valued at $88,000. Finally, Dimensional Fund Advisors LP boosted its holdings in SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after acquiring an additional 6,205 shares during the last quarter. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.